Bio-Techne

TECH

Market cap $8.09B

Bio-Techne Corporation (TECH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bio-Techne Corporation (TECH) Q3 2026 Earnings Call Transcript

Bio-Techne slips after Q3 EPS miss and revenue decline, despite operating margin expansion and strong growth in key segments.

Techne (TECH) came out with quarterly earnings of $0.53 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.56 per share a year ago.

Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. ​academic funding weighed on demand for its drug-development ‌products.

MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026. Third Quarter FY2026 Highlights Reported and organic revenue declined 2% to $311.4M, negatively impacted by prior‑year GMP fast‑track orders and timing of large Commercial Supply shipments GAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56 Large pharma delivered the sixth consecutive quarter of double‑digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low‑single‑digit growth Growth vectors performed well, with mid‑single‑digit growth in Proteomic Analysis instruments, mid‑teens growth in Spatial Biology, and nearly 50% growth in GMP proteins excluding fast‑track customers "The Bio‑Techne team delivered solid execution amid a mixed end‑market environment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne.

MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be payable May 29, 2026, to all common shareholders of record on May 18, 2026.

MINNEAPOLIS, May 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026, at 9:20 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the outlook.

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.